araag2/HINT huggingface dataset:
Clinical trial NCT00635232 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: irbesartan, placebo, ps433540, ps433540, ps433540
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C, CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C(COCC)=C1)C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 18 - 70 years

          -  Mean seated Systolic Blood Pressure (SBP) ≥ 140 mmHg and < 180 mmHg and mean seated
             Diastolic Blood Pressure (DBP) > 90 and < 109 mmHg at two consecutive qualifying
             visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two
             consecutive qualifying visits must be ≤ 10 mmHg.

          -  Women of child-bearing potential (WOCBP) must use two reliable forms of contraception
             if sexually active. Alternatively, female subjects must be postmenopausal (for at
             least 1 year).

        Exclusion Criteria:

          -  Subjects with serious disorders which may limit the ability to evaluate the efficacy
             or safety of PS433540, including cardiovascular (includes subjects who are known to
             have coronary artery disease), renal (including the absence of one kidney), pulmonary,
             hepatic, gastrointestinal (including clinically significant malabsorption),
             endocrine/metabolic, hematologic, neurologic and psychiatric diseases.

          -  History of malignancy other than adequately treated basal cell or squamous cell skin
             cancer.

          -  Subjects with a history of myocardial infarction or New York Heart Association (NYHA)
             class II-IV heart failure.

          -  Subjects with a history of cerebrovascular accident or transient ischemic attack.

          -  Subjects with clinically significant cardiac conduction defects, including second or
             third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus
             syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any
             arrhythmia requiring medication.

          -  Subjects with hemodynamically significant valvular disease.

          -  Subjects with history of type 1 diabetes mellitus and subjects with a history of type
             2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or
             exenatide) are excluded.
Clinical trial NCT00619099 (phase 2, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: decitabine, decitabine
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

        Each patient must meet the following criteria to be enrolled in this study:

          1. Male or female patients age 18 years and older.

          2. Patients must sign an institutional review board (IRB)-approved informed consent form,
             and understand the investigational nature of this study and its potential hazards
             prior to initiation of any study-specific procedures or treatment.

          3. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          4. Adequate renal and hepatic function (creatinine < 2 times upper limit of normal, total
             bilirubin of < 2 times upper limit of normal, and AST and ALT ≤ 2 times upper limit of
             normal) unless proven to be related to disease infiltration.

          5. Female patients need a negative serum or urine pregnancy test within 7 days prior to
             study drug administration (applies only if patient is of childbearing potential.
             Non-childbearing is defined as ≥ 1 year postmenopausal or surgically sterilized).

          6. Women of childbearing potential and men must use contraception. Men and women must
             continue birth control for the duration of the study.

          7. Patients with Low or Intermediate-1 Risk MDS by the International Prognostic Scoring
             System (IPSS) classification.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from the study:

          1. Women who are pregnant or nursing.

          2. Those who have received prior therapy with decitabine.

          3. Prior therapy with azacitidine (Vidaza®).

          4. Those who received growth factor support or lenalidomide in the 30 days prior to the
             first dose of decitabine.

          5. Those who have received an investigational agent 30 days prior to the first dose of
             decitabine.

          6. Patients with active, uncontrolled, systemic infection considered opportunistic, life
             threatening or clinically significant; or any severe, concurrent disease, which, in
             the judgment of the Investigator and after discussion with the Sponsor and Primary
             Investigator, would make the patient inappropriate for study entry.
Clinical trial NCT00453635 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, carboplatin, herceptin, vinorelbine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Performance status (WHO) 0-2

          -  Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior
             chemotherapy received

          -  HER-2 overexpression 2+ or 3+ using IHC or FISH +

          -  Measurable disease not in a prior irradiation field (no other concurrent chemotherapy
             agents)

          -  No more than 25% of myeloproductive bone marrow irradiated (more than 4 weeks since
             prior radiotherapy and recovered)

          -  More than 6 months since prior adjuvant or neoadjuvant chemotherapy and recovered

          -  No prior first line chemotherapy for metastatic disease

          -  Endocrine therapy is allowed as adjuvant or first line treatment for metastatic
             disease

          -  Paraffin block from the primary tumor available in the research lab

          -  Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count >
             100000/mm^3, hemoglobin > 9 gr/mm^3)

          -  Adequate liver (Bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times
             upper limit of normal) and renal function (creatinine < 2mg/dl)

          -  Adequate cardiac function (LVEF > 50%)

          -  Informed consent

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce
             P-450 cytochrome

          -  Positive pregnancy test

          -  Motor or sensory neuropathy > grade 1 according to NCIC Τoxicity Criteria

          -  Patients with brain metastatic disease who has not been irradiated or uncontrolled
             brain metastatic disease after irradiation

          -  History of allergic reaction attributed to docetaxel

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except cured basal cell skin
             carcinoma and cervical carcinoma in situ
Clinical trial NCT00483717 (phase 2, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: ketorolac tromethamine, placebo
SMILES: OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of migraine with or without aura (IHS criteria 1.1 and 1.2.1);

          -  Onset of migraine prior to age 50;

          -  2-8 moderate to severe migraine headaches per month

        Exclusion Criteria:

          -  Subjects receiving any investigational drug within 30 days before study entry;

          -  More than 15 headache days per month;

          -  Known allergy or hypersensitivity to ketorolac and/or excipients;

          -  Allergy to aspirin or other NSAIDs;

          -  Currently receiving other NSAIDs or aspirin;

          -  Medical history that would preclude NSAID use
Clinical trial NCT00649311 (phase 2, status: terminated)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: eplerenone, losartan
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Reason stopped: 
    poor enrollment; termination not due to safety reasons.
  
Eligibility criteria:

        Inclusion Criteria:

          -  History of mild to moderate hypertension, or newly diagnosed hypertension, defined as
             seDBP ≥90 mmHg and <110 mmHg and seSBP <180 mmHg

          -  Withdrawal of all previous antihypertensives prior to the single-blind placebo run-in
             period and the double-blind treatment period

        Exclusion Criteria:

          -  Secondary hypertension (e.g., renal, renovascular, or adrenocortical disease,
             pheochromocytoma, Cushing's syndrome, primary aldosteronism, iatrogenic), severe
             hypertension, or malignant hypertension

          -  The patient cannot withdraw from antihypertensives by any route including diuretics,
             alpha-blockers, betablockers, calcium channel blockers, ACE-I, ARB, or other
             medications affecting blood pressure; patients who have stable angina and have not had
             their nitrate dosage changed within the past three months (i.e., on a stable
             maintenance dose) are eligible for this study; sildenafil citrate, theophylline, or
             papaverine must not be taken within 24 hours prior to a clinic visit
Clinical trial NCT01350128 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: pt001 mdi, ipratropium bromide hfa inhalation aerosol
SMILES: [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N+]2(C)C(C)C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70

          -  A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
Clinical trial NCT01194258 (phase 2, status: completed)
Conditions: diabetes mellitus, type ii
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: insulin lispro, insulin aspart, recombinant human hyaluronidase ph20, insulin glulisine, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females ≥18 years

          -  Type 2 diabetes mellitus (T2DM) treated with insulin ≥12 months and prandial insulin
             (at least 2 meals per day) for ≥2 months

          -  Body mass index (BMI) of 23.0 to 45.0 kilograms per meter squared (kg/m^2)

          -  Glycosylated hemoglobin (HbA1C) level 7.0 to 8.5%, inclusive

          -  Fasting C-peptide <0.6 nanograms per milliliter (ng/mL)

          -  Willingness to use insulin glargine twice a day as basal insulin for the duration of
             the study

          -  Willingness to avoid use of an insulin infusion pump or unblinded continuous glucose
             monitoring (CGM) during the study

        Exclusion Criteria:

          -  Known or suspected allergy to any component of any of the study drugs

          -  Exclusive use of pre-mixed insulins

          -  Use of pramlintide, exenatide, and/or liraglutide within 30 days of screening

          -  Use of sulfonylureas within two months of screening

          -  Use of drugs (such as corticosteroids or antimetabolites) that could interfere with
             the interpretation of study results or are known to cause clinically relevant
             interference with insulin action, glucose utilization, or recovery from hypoglycemia,
             during the study or within 30 days of screening

          -  Recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or
             hypoglycemic unawareness, as judged by the investigator
Clinical trial NCT00169104 (phase 2/phase 3, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: g-csf, trastuzumab, vinorelbine, g-csf, saline placebo
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, [Na+].[Cl-]
Reason stopped: 
    closed due to achievement of primary study endpoint
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have pathological confirmation of carcinoma of the breast.

          -  Patients must have metastatic breast cancer by documented clinical or radiological
             assessment.

          -  Immunohistochemical analysis of HER-2/neu expression on paraffin-embedded specimens
             will be performed. HER-2/neu overexpression will be qualitatively scored as 0, 1+, 2+,
             or 3+, with 3+ indicating the strongest positivity. Fluorescence In Situ Hybridization
             (FISH) analyses will also be performed on these patients. Patients with 2+ to 3+
             overexpression of HER-2/neu (membranous staining) are eligible, regardless of the
             results of the FISH analysis.

          -  Age ≥18 years.

          -  Karnofsky performance status ≥ 60%.

          -  Adequate hepatic, renal, and hematologic function.

          -  Prior treatment with trastuzumab will be allowed.

          -  All patients must have adequate cardiac function (defined as left ventricular ejection
             fraction ≥ 45%) documented by echocardiogram or MUGA scan.

          -  Premenopausal women will be required to have a negative urine or serum pregnancy test
             and to use an effective form of contraception.

          -  Patients with a history of brain metastases are permitted as long as it has been at
             least 30 days since definitive treatment, they are clinically stable and a magnetic
             resonance imaging scan of the brain demonstrates control of the lesion(s).

          -  All patients must give written informed consent indicating they are aware of the
             investigational nature of this treatment, as well as the risks and benefits of this
             protocol.

        Exclusion Criteria:

          -  No treatment with chemotherapy or trastuzumab will be allowed within four weeks of
             study entry.

          -  Prior therapy with vinorelbine.

          -  Known history of hypersensitivity to trastuzumab, Chinese hamster ovary (CHO) cell
             proteins, or any component of these products.

          -  History of current unstable angina, symptomatic congestive heart failure, or
             myocardial infarction within the last 6 months.

          -  Pregnant women are excluded.

          -  History of a known hypersensitivity to E. coli-derived proteins, filgrastim, or any
             component of the product.
Clinical trial NCT02157116 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, docetaxel, pegfilgrastim
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Reason stopped: 
    insufficient accrual to meet analysis goals
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with documented stage III NSCLC (IIIA or IIIB, without malignant
             pleural/pericardial effusion) are eligible for enrollment if they are considered
             appropriate for treatment with chemotherapy, radiation, or surgery;

          -  IIIA: T1-3 N2 M0, T3 N1 M0

          -  IIIB: T4 N0-2 M0, T 1-4 N3 M0

          -  Measurable or evaluable disease

          -  Previously untreated with chemotherapy or radiotherapy for lung cancer;

          -  No brain metastases;

          -  No prior XRT

          -  Performance status 0-2

          -  ≥18 years of age

          -  Informed Consent

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

          -  Platelets ≥ 100 x 109/L

          -  Bilirubin ≤ 1.5 x upper limit of normal for the institution (ULN)

          -  SGOT and SGPT ≤ 2.5 x ULN for the institution

          -  Creatinine ≤ 1.6 mg/dL

          -  Hemoglobin ≥ 8.0 g/dL

          -  Peripheral neuropathy ≤ grade 1

        Exclusion Criteria:

          -  Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN® insulin,
             L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A);

          -  Use of IV systemic antibiotics within 72 hours prior to chemotherapy;

          -  Known HIV infection

          -  Lithium or cytokines within 2 weeks prior of entry

          -  Additional concurrent investigational drugs

          -  History of myelodysplastic syndrome

          -  Pregnant, nursing or having unprotected sex

          -  Not available for follow-up assessment

          -  Unable to comply with protocol procedures

          -  Illnesses that may compromise ability to give informed consent.

          -  Patients with a history of severe hypersensitivity reaction to Taxotere® or other
             drugs formulated with polysorbate 80.
Clinical trial NCT00299260 (phase 2, status: unknown status)
Conditions: cytomegalovirus infections
ICD codes: P35.1
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent and/or assent must be obtained from the patient.

          -  Patients must be 18 years of age or older.

          -  Awaiting a liver or kidney transplant.

          -  All female patients with childbearing potential must have a negative pregnancy test
             prior to each vaccination.

          -  All females of childbearing potential must agree to use an effective barrier method of
             birth control while receiving the vaccine and for 30 days after completion of the
             course of vaccine. Other contraception in addition to barrier methods is permitted.

          -  Among the CMV seropositives, HLA type compatible with tetramer assays (currently A2,
             A24, B7, B8, B35). (seronegatives of any HLA type are eligible).

        Exclusion Criteria:

          -  Patient unable or unwilling to provide and sign an informed consent or assent.

          -  If a patient who is competent to give informed consent enters the trial but
             subsequently becomes incompetent, they will be withdrawn.

          -  Pregnant or breastfeeding females.

          -  Participation in another clinical trial of a vaccine or of a systemic drug in the 4
             weeks preceding the first trial vaccination (participation in trials of medical
             devices/ procedures is allowed).

          -  Planned participation in another clinical trial of a vaccine or of a systemic drug
             during the present trial period (participation in trials of medical devices/
             procedures is allowed).

          -  Systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or a vaccine containing the same
             substances.

          -  Blood or blood-derived products received in the past 3 months (except albumin).

          -  Current thrombocytopenia or bleeding disorder contraindicating IM vaccination.

          -  Among the seropositives, HLA type incompatible with tetramer assays (seronegatives of
             any HLA type are eligible).

          -  Requiring emergency transplant for fulminant liver failure.

          -  Patients known to be HIV positive.